A personalized treatment strategy formalizes evidence-based treatment selection by mapping patient information to a recommended treatment. Personalized treatment strategies can produce better patient outcomes while reducing cost and treatment burden. Thus, among clinical and intervention scientists, there is a growing interest in conducting randomized clinical trials when one of the primary aims is estimation of a personalized treatment strategy. However, at present, there are no appropriate sample size formulae to assist in the design of such a trial. Furthermore, because the sampling distribution of the estimated outcome under an estimated optimal treatment strategy can be highly sensitive to small perturbations in the underlying generative model, sample size calculations based on standard (uncorrected) asymptotic approximations or computer simulations may not be reliable. We offer a simple and robust method for powering a single stage, two-armed randomized clinical trial when the primary aim is estimating the optimal single stage personalized treatment strategy. The proposed method is based on inverting a plugin projection confidence interval and is thereby regular and robust to small perturbations of the underlying generative model. The proposed method requires elicitation of two clinically meaningful parameters from clinical scientists and uses data from a small pilot study to estimate nuisance parameters, which are not easily elicited. The method performs well in simulated experiments and is illustrated using data from a pilot study of time to conception and fertility awareness.
personalized treatment strategy sample size, pilot data randomized trial design, optimal treatment strategy estimation, precision medicine trial design, individualized treatment selection methodology, adaptive treatment strategy clinical trial, personalized medicine sample size calculation, treatment heterogeneity clinical trial, pilot study treatment personalization, statistical methods personalized treatment
PMID 26506890 26506890 DOI 10.1002/sim.6783 10.1002/sim.6783
Cite this article
Laber, E. B., Zhao, Y. Q., Regh, T., Davidian, M., Tsiatis, A., Stanford, J. B., Zeng, D., Song, R., & Kosorok, M. R. (2016). Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy. *Statistics in medicine*, *35*(8), 1245-1256. https://doi.org/10.1002/sim.6783
Laber EB, Zhao YQ, Regh T, Davidian M, Tsiatis A, Stanford JB, et al. Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy. Stat Med. 2016;35(8):1245-1256. doi:10.1002/sim.6783
Laber, E. B., et al. "Using pilot data to size a two-arm randomized trial to find a nearly optimal personalized treatment strategy." *Statistics in medicine*, vol. 35, no. 8, 2016, pp. 1245-1256.
Regular welfare assessments are essential for identifying and addressing the physical, behavioral, and emotional needs of shelter dogs, thereby ensuring their well-being and improving chances for adop...
GBD 2021 AEMT Collaborators, 2026The Korean journal of internal medicine
BACKGROUND/AIMS: This study aims to evaluate the global burden of adverse effects of medical treatment (AEMT) using data from the Global Burden of Disease Study (GBD) 2021.
METHODS: Data were extract...
GBD 2023 Disease and Injury and Risk Factor Collaborators, 2025Lancet (London, England)
BACKGROUND: For more than three decades, the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) has provided a framework to quantify health loss due to diseases, injuries, and associate...
GBD 2023 Causes of Death Collaborators, 2025Lancet (London, England)
BACKGROUND: Timely and comprehensive analyses of causes of death stratified by age, sex, and location are essential for shaping effective health policies aimed at reducing global mortality. The Global...